Man Group’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $69.2M | Sell |
139,233
-97,565
| -41% | -$43.2M | 0.11% | 203 |
|
|
2026
Q1 | $106M | Sell |
236,798
-143,937
| -38% | -$67.1M | 0.19% | 122 |
|
|
2025
Q4 | $173M | Buy |
380,735
+17,961
| +5% | +$7.74M | 0.29% | 69 |
|
|
2025
Q3 | $142M | Buy |
362,774
+235,156
| +184% | +$98.3M | 0.25% | 95 |
|
|
2025
Q2 | $56.8M | Buy |
127,618
+112,434
| +740% | +$51.8M | 0.11% | 213 |
|
|
2025
Q1 | $7.36M | Sell |
15,184
-73,542
| -83% | -$34.3M | 0.02% | 850 |
|
|
2024
Q4 | $35.7M | Buy |
88,726
+37,008
| +72% | +$17.2M | 0.09% | 249 |
|
|
2024
Q3 | $24.1M | Sell |
51,718
-145,578
| -74% | -$69.9M | 0.06% | 389 |
|
|
2024
Q2 | $92.5M | Sell |
197,296
-330,628
| -63% | -$144M | 0.23% | 93 |
|
|
2024
Q1 | $221M | Buy |
527,924
+173,126
| +49% | +$73.2M | 0.56% | 21 |
|
|
2023
Q4 | $144M | Buy |
+354,798
| New | +$131M | 0.4% | 39 |
|
|
2023
Q3 | – | Sell |
-382,820
| Closed | -$134M | – | 68 |
|
|
2023
Q2 | $135M | Buy |
+382,820
| New | +$129M | 0.42% | 36 |
|
|
2023
Q1 | – | Sell |
-576,398
| Closed | -$173M | – | 46 |
|
|
2022
Q4 | $166M | Buy |
576,398
+340,716
| +145% | +$104M | 0.6% | 19 |
|
|
2022
Q3 | $68.2M | Buy |
+235,682
| New | +$67.8M | 0.32% | 59 |
|
|
2022
Q2 | – | Sell |
-430,760
| Closed | -$115M | – | 159 |
|
|
2022
Q1 | $112M | Sell |
430,760
-532,765
| -55% | -$126M | 0.39% | 41 |
|
|
2021
Q4 | $212M | Sell |
963,525
-247,918
| -20% | -$48.2M | 0.68% | 19 |
|
|
2021
Q3 | $220M | Buy |
1,211,443
+371,319
| +44% | +$72.5M | 0.77% | 14 |
|
|
2021
Q2 | $169M | Buy |
840,124
+202,762
| +32% | +$42.4M | 0.6% | 19 |
|
|
2021
Q1 | $137M | Sell |
637,362
-290,549
| -31% | -$63.8M | 0.6% | 20 |
|
|
2020
Q4 | $219M | Buy |
927,911
+217,679
| +31% | +$49.9M | 0.96% | 10 |
|
|
2020
Q3 | $193M | Buy |
710,232
+117,797
| +20% | +$32.5M | 0.76% | 15 |
|
|
2020
Q2 | $172M | Sell |
592,435
-75,565
| -11% | -$20.5M | 0.87% | 16 |
|
|
2020
Q1 | $159M | Buy |
668,000
+431,635
| +183% | +$99M | 1.03% | 12 |
|
|
2019
Q4 | $51.8M | Buy |
236,365
+171,786
| +266% | +$34.8M | 0.17% | 120 |
|
|
2019
Q3 | $10.9M | Sell |
64,579
-67,846
| -51% | -$12M | 0.04% | 545 |
|
|
2019
Q2 | $24.3M | Buy |
132,425
+25,460
| +24% | +$4.45M | 0.09% | 281 |
|
|
2019
Q1 | $19.7M | Sell |
106,965
-123,977
| -54% | -$22.9M | 0.07% | 322 |
|
|
2018
Q4 | $38.3M | Buy |
230,942
+135,385
| +142% | +$23.5M | 0.17% | 128 |
|
|
2018
Q3 | $18.4M | Sell |
95,557
-40,728
| -30% | -$7.25M | 0.07% | 354 |
|
|
2018
Q2 | $23.2M | Buy |
136,285
+23,668
| +21% | +$3.67M | 0.1% | 224 |
|
|
2018
Q1 | $18.4M | Buy |
+112,617
| New | +$18.4M | 0.08% | 258 |
|
Other funds holding VRTX
Man Group's VRTX Position: Q2 2026 in Review
Man Group reduced its Vertex Pharmaceuticals (VRTX) stake by 41% in Q2 2026, selling an estimated $43.2M and leaving 139,233 shares worth $69.2M. The position accounts for 0.11% of the portfolio, ranked #203.
Man Group first reported a position in VRTX in Q1 2018 and has held it in 31 quarters since. The position peaked at $221M in Q1 2024. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Man Group held 139,233 shares of Vertex Pharmaceuticals worth $69.2M as of Q2 2026.
- Man Group sold 97,565 Vertex Pharmaceuticals shares in Q2 2026, an estimated $43.2M.
- Vertex Pharmaceuticals made up 0.11% of Man Group's portfolio in Q2 2026, its #203 holding.
- Man Group first reported a position in Vertex Pharmaceuticals in Q1 2018 and has held it in 31 quarters since.
- Man Group's Vertex Pharmaceuticals position peaked at $221M in Q1 2024.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.